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Abstract
The consolidation of scientific knowledge proceeds through the interpretation and then distillation of data presented in
research reports, first in review articles and then in textbooks and undergraduate courses, until truths become accepted as
such both amongst ‘‘experts’’ and in the public understanding. Where data are collected but remain unpublished, they
cannot contribute to this distillation of knowledge. If these unpublished data differ substantially from published work,
conclusions may not reflect adequately the underlying biological effects being described. The existence and any impact of
such ‘‘publication bias’’ in the laboratory sciences have not been described. Using the CAMARADES (Collaborative Approach
to Meta-analysis and Review of Animal Data in Experimental Studies) database we identified 16 systematic reviews of
interventions tested in animal studies of acute ischaemic stroke involving 525 unique publications. Only ten publications
(2%) reported no significant effects on infarct volume and only six (1.2%) did not report at least one significant finding.
Egger regression and trim-and-fill analysis suggested that publication bias was highly prevalent (present in the literature for
16 and ten interventions, respectively) in animal studies modelling stroke. Trim-and-fill analysis suggested that publication
bias might account for around one-third of the efficacy reported in systematic reviews, with reported efficacy falling from
31.3% to 23.8% after adjustment for publication bias. We estimate that a further 214 experiments (in addition to the 1,359
identified through rigorous systematic review; non publication rate 14%) have been conducted but not reported. It is
probable that publication bias has an important impact in other animal disease models, and more broadly in the life
sciences.
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opinion and public understanding, will be biased. This is the ‘‘file
drawer problem’’ [2,3]: at its most extreme, the 95% of studies
that were truly neutral (that is, which reported no significant
effects) remain in the files of the investigators, the 5% of
experiments that were falsely positive are published, and reviewers
conclude—falsely—that the literature represents biological truth.
The consequences of the drawing of erroneous conclusions
would be troubling if it involved, for instance, the interpretation of
data from clinical trials; indeed, the recognition of a substantial
publication bias in this literature has led to the introduction of
clinical trial registration systems to ensure that those summarising
research findings are at least aware of all relevant clinical trials that
have been performed [4]. Publication bias has also been observed
in reports of genetic association studies [5] and in ecology and
evolution, in which 40% of meta-analyses were confounded by
publication bias, and adjusting for publication bias might have
altered the conclusions in around one-third of cases [6]. A related
group of biases, the citation biases [7], can be addressed through
rigorous systematic review, in that an attempt is made to include
all relevant publications describing data meeting predefined

Introduction
Few publications describing natural phenomena are in themselves sufficient to change our understanding of the world, and
knowledge advances through the summarising of data in
conference presentations, review articles, and books. Traditionally
this process has been rather haphazard, with sometimes partisan
experts using narrative review articles to emphasise their own
particular perspective. Attempts have been made to account for
this bias using the technique of systematic review, in which there is
prespecification of the biological question being addressed, the
methods through which contributing data will be identified, and
the criteria that will be used to select which data are included in
the analysis [1]. While systematic reviewers often go to some
lengths to identify unpublished data sources, both approaches are
potentially confounded by the ability to include only available
data. If experiments have been conducted but are not available to
reviewers, and if the results of these experiments as a group are not
the same as results from experiments that were published, then
both narrative and systematic reviews, and the resulting expert
PLoS Biology | www.plosbiology.org
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reported, and the qualitative rather than quantitative nature of
many of those outcomes.
Since 2004 the Collaborative Approach to Meta-Analysis and
Review of Animal Data in Experimental Studies (CAMARADES)
has curated data collected in the context of systematic reviews of
reports of studies describing the efficacy in animals of candidate
interventions for stroke [10–21]. Here we use that dataset, which
includes quantitative data for reported outcomes from individual
experiments, to estimate the prevalence and impact of publication
bias in laboratory science.

Author Summary
Publication bias is known to be a major problem in the
reporting of clinical trials, but its impact in basic research
has not previously been quantified. Here we show that
publication bias is prevalent in reports of laboratory-based
research in animal models of stroke, such that data from as
many as one in seven experiments remain unpublished.
The result of this bias is that systematic reviews of the
published results of interventions in animal models of
stroke overstate their efficacy by around one third.
Nonpublication of data raises ethical concerns, first
because the animals used have not contributed to the
sum of human knowledge, and second because participants in clinical trials may be put at unnecessary risk if
efficacy in animals has been overstated. It is unlikely that
this publication bias in the basic sciences is restricted to
the area we have studied, the preclinical modelling of
the efficacy of candidate drugs for stroke. A related article
in PLoS Medicine (van der Worp et al., doi:10.1371/
journal.pmed.1000245) discusses the controversies and
possibilities of translating the results of animal experiments into human clinical trials.

Results
Systematic Identification of Previous Reports of
Publication Bias in Animal Models of Human Disease
A search for publications that might have addressed this
problem previously identified 71 publications (Text S1). Of these,
11 described meta-analyses of studies reporting the animal
modelling of human disease (including three CAMARADES
reviews); six reported testing for the presence of publication bias
(using funnel plot asymmetry or Egger regression), and publication
bias was reported in four (Figure 1). No study gave quantitative
estimates of the impact on effect size of publication bias.

inclusion or exclusion criteria. However, until recently there has
been a paucity of systematic reviews of animal studies [8].
The extent and any impact of publication bias in the
experimental sciences are not clear. Timmer and colleagues
investigated the process of publication for abstracts submitted to a
leading gastrointestinal conference, and suggested both that the
most responsibility for nonpublication rested with the authors
(76% of unpublished projects were never submitted as a
manuscript) and that for basic science studies there was no
relationship between the rate of publication and whether the study
reported positive, neutral, or negative findings [9]. It has
previously not been possible to ascertain the impact of publication
bias in animal studies because of the paucity of systematic reviews
and meta-analyses, the substantial heterogeneity in the research
questions asked in experimental science and in the outcomes

Source Data
As of August 2008 the CAMARADES database contained
details from systematic reviews of 16 interventions tested in animal
models of stroke. This database comprises data from 525 unique
data sources, comprising 514 unique publications (15 contributed
data to more than one review) and 11 unpublished communications, describing 1,359 experiments involving 19,956 animals
(Table 1). Of these, only ten publications (2%; one publication
[22] was represented in reviews of both tirilazad and tPA)
described no significant effect on infarct volume, although four
reported other statistically significant findings [23–26].

Prevalence of Publication Bias
For individual interventions, visual inspection of funnel plots
suggested that only hypothermia and tissue plasminogen activator
(tPA) had obvious inverted funnel shapes (examples for hypothermia, tPA, stem cells, and growth factors are shown in Figure 2a–
2d). These interventions represented the largest individual datasets
(222 experiments involving 3,256 animals and 256 experiments
involving 4,029 animals, respectively). However, Egger regression
suggested significant asymmetry of all 16 datasets (examples in
Figure 2e–2h). In every case the intercept of the regression line was
positive, suggesting an excess of imprecise studies reporting large
effect sizes over that which would be expected from the overall
distribution of the data. Trim-and-fill analysis of individual
datasets (examples in Figure 2i–2l) suggested asymmetry affecting
ten of 16 interventions, with six interventions without significant
asymmetry (minocycline, NXY-059, piracetam, stem cells, tirilazad, and thrombolytics other than tPA). Funnel plotting of the
entire dataset showed asymmetry, confirmed by both Egger
regression and trim-and-fill (Figure 3; Table 2).

Impact of Publication Bias
Trim-and-fill imputes the number and most probable results of
unpublished experiments to calculate an estimate of what the
effect size would be in the absence of publication bias [27]
(Figure 2i–2l) The proportion of missing experiments ranged from
5% for tPA to 36% for interleukin 1 receptor antagonist (IL1 RA).
Overall, 214 experiments were considered ‘‘missing,’’ or 16%
experiments additional to those identified through systematic

Figure 1. QUOROM chart of fate of 71 publications identified in
systematic search for studies reporting the quantitative impact
of publication bias in reports of animal experiments modelling
human disease.
doi:10.1371/journal.pbio.1000344.g001
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Table 1. Meta-analyses included in this analysis.

Intervention

No. of Data Sources

No. of Experiments

No. of Animals

Reported Effect Size (95%Cl)

Estrogens [10]

27

99

1,452

26.7% (20.4%–33.0%)

FK506 [12]

27

96

1,596

32.0% (27.8%–36.3%)

Growth factors

70

128

1,750

29.7% (25.9%–33.4%)

Hypothermia [40]

98

222

3,256

43.5% (40.1%–47.0%)

IL1-RA [21]

23

44

784

38.2% (31.2%–45.1%)

Melatonin [13]

12

29

443

42.1% (35.7%–48.5%)

Minocycline

8

25

535

30.9% (24.1%–37.6%)

Nicotinamide [11]

11

57

719

29.2% (23.0%–35.5%)

NOS donors [19]

17

40

483

21.4% (13.7%–29.1%)

NOS inhibitors [41]

52

148

1,998

22.2% (17.1%–27.3%)

NXY-059 [14]

9

29

408

43.8% (34.7%–52.8%)

Piracetam and related compounds [18]

5

14

197

29.6% (16.1%–44.4%)

Stem cells

46

112

1,352

29.6% (23.7%–35.4%)

Tirilazad [16]

18

34

544

31.9% (23.1%–40.7%)

tPA [15]

105

256

4,029

22.5% (19.2%–25.9%)

Other thrombolyics

12

26

410

46.6% (35.7%–57.5%)

Pooled analysis

525*

1,359

19,956

31.3% (29.7%–32.8%)

*Fifteen data sources were represented in more than one review and are included only once in the pooled analysis.
doi:10.1371/journal.pbio.1000344.t001

Figure 2. Example funnel plots, Egger regressions, and trim-and-fill plots. Data from meta-analyses of hypothermia (a,e,i), tPA (b,f,j), stem
cells (c,g,k), and growth factors (d,h,l). (a–d) Funnel plots showing precision plotted against effect size. In the absence of publication bias the points
should resemble an inverted funnel. (e–h) Egger regression showing precision plotted against the standardised effect size. In the absence of
publication bias the regression line should pass through the origin. (i–l) Funnel plots showing the data from (a) to (d) in black, and the additional
missing studies imputed by trim-and-fill in red.
doi:10.1371/journal.pbio.1000344.g002
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the number of experiments contributing to a meta-analysis and
either the absolute or the relative overstatement of efficacy, and
there was no relationship between the precision of individual
studies and their methodological quality. Considering all data
together, overall efficacy was reduced from 31.2% (95% CI
29.7%–32.8%) to 23.8% (95% CI 22.2%–25.5%; p,0.0001)
(relative overstatement of efficacy 31.1%; absolute overstatement
of efficacy 7.4%).

Discussion
These data provide to our knowledge the first quantitative
estimates of the impact of publication bias in the literature
describing animal experiments modelling human disease. Only
2.2% of publications identified in the included reviews did not
report any significant findings. While our approach can provide at
best only approximations of the magnitude of the problem, our
data suggest that effect sizes are inflated by around one-third, and
we estimate that around one-sixth of experiments remain
unpublished. Many would consider these to be conservative
estimates, and indeed a recent systematic review of individual
animal data supporting the efficacy of NXY-059 showed that two
of four unpublished experiments identified in the course of that
review were neutral [28]. The different methods used to assess the
presence of publication bias gave somewhat different results, which
may reflect the different sensitivities of these approaches.
However, it is likely that publication bias is highly prevalent in
this literature, and this is likely to bias the conclusions drawn in
both narrative and systematic reviews.
The different methods used to ascertain publication bias gave
somewhat different results; Egger regression suggested bias for all
16 interventions, whereas trim-and-fill suggested bias for ten of 16
interventions. Importantly, the median number of publications for
those interventions in which trim and fill suggested publication
bias was higher (27) than those in which publication bias was not
found (10.5), suggesting that when publication number is small the
trim-and-fill approach may lack statistical power compared with
Egger regression.
In discussion of factors that might result in funnel plot
asymmetry in animal studies it is important to note that, given
their small size and in contrast to clinical trials, variation in study
precision relates more to underlying biological variability and to
measurement error than to study size. However, there are a
number of factors other than publication bias that can cause
funnel plot asymmetry [29]:
First, because studies of poorer methodological quality tend to
overstate effect sizes [30], lower precision in these studies would
lead to funnel plot asymmetry. However, we found no association
between study precision and methodological quality in the
publications contributing to this analysis.
Second, the effect size may vary according to the size of
individual studies. In clinical trials, smaller studies may involve
patients at greater risk of an adverse outcome, in whom the
intervention is proportionately more effective; or higher doses or
more powerful interventions may be used in smaller studies; or
smaller studies may focus on particular groups in whom the
intervention is more effective. However, none of these features
apply to the animal studies examined here.
Third, the studies identified in the individual reviews may not be
representative of all studies published. However, the included
reviews used detailed search strategies involving multiple electronic
databases and conference abstracts; had no language restriction; and
where duplicate publication had occurred only one publication was
included (see Methods). Selection bias is therefore unlikely.

Figure 3. Plots describing the complete dataset. Funnel plot (a),
Egger regression (b), and trim-and-fill plots (c). See Figure 1 legend for
details.
doi:10.1371/journal.pbio.1000344.g003

review (Figure 3c). This is the best estimate for the proportion of
studies which were conducted but not reported. Of the ten
interventions identified through trim-and-fill as exhibiting significant publication bias, the adjusted effect size was significantly
lower than that estimated through conventional meta-analysis in
seven. The relative overstatement of efficacy ranged from 2.7% for
melatonin to 124.4% for estrogens, and the absolute overstatement
of efficacy ranged from 1.1% for melatonin to 14.8% for estrogens,
(Figure 4; Table 2). There was no significant association between
PLoS Biology | www.plosbiology.org
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Table 2. Prevalence and potential impact of publication bias.

Bias with
METATRIM

Additional
%Studies
Considered
‘‘Missing’’

METATRIM Adjusted
Effect Size (95%Cl)

Absolute
Overstatement of
Efficacy

Relative
Overstatement of
Efficacy

+

+

24

11.9% (4.6%–19.2%)a

32.0% (27.8%–36.3%)

+

14.8% (8.0%–21.6%)

124.4%

+

30

21.9% (17.5%–26.3%)a

10.1% (5.8%–14.4%)

Growth factors

29.7% (25.9%–33.4%)

46.1%

+

+

14

25.1% (21.2%–28.9%)a

4.6% (0.9%–8.3%)

Hypothermia

18.3%

43.5% (40.1%–47.0%)

+

+

20

35.4% (31.7%–39.1%)a

8.1% (4.5%–11.6%)

22.9%

IL1-RA

38.2% (31.2%–45.1%)

+

+

36

25.4% (18.4%–32.4%)a

12.8% (5.9%–19.7%)

50.4%

Melatonin

42.1% (35.7%–48.5%)

+

+

14

41.0% (34.8%–47.3%)

1.1% (25.1% to 7.4%)

2.7%

Minocycline

30.9% (24.1%–37.6%)

+

2

0

No adjustment

Nicotinamide

29.2% (23.0%–35.5%)

+

+

24

21.8% (14.9%–28.6%)a

7.4% (0.8%–13.9%)

33.9%

NOS donors

21.4% (13.7%–29.1%)

+

+

25

14.0% (6.4%–21.6%)a

7.4% (20.1% to 14.9%)

52.9%

NOS inhibitors

22.2% (17.1%–27.3%)

+

+

13

14.7% (8.9%–20.6%)a

7.5% (2.0%–13.0%)

51.0%

Intervention

Reported
Effect Size
(95%Cl)

Bias with
Egger
Regression

Estrogens

26.7% (20.4%–33.0%)

FK506

NXY-059

43.8% (34.7%–52.8%)

+

2

0

No adjustment

Piracetam and
related compounds

29.6% (16.1%–44.4%)

+

2

0

No adjustment

Stem cells

29.6% (23.7%–35.4%)

+

2

0

No adjustment

—

—

—

Tirilazad

31.9% (23.1%–40.7%)

+

2

0

No adjustment

tPA

22.5% (19.2%–25.9%)

+

+

5

19.9% (16.4%–23.3%)

Other Thrombolytics

46.6% (35.7%–57.5%)

+

2

0

No adjustment

Pooled analysis

31.3% (29.7%–32.8%) +

+

214b

23.8% (22.2%–25.5)a

—
2.6% (20.7% to 6.0%)

13.1%
-

7.5% (5.9%–9.1%)

31.1%

Duval and Tweedie nonparametric trim-and-fill provides an estimate of the number of unpublished studies, and provides an estimate of what the observed efficacy
might have been had these studies been available. Where no adjustment is made there are either not enough data to infer the number of missing studies or there is no
publication bias.
a
p,0.05 versus unadjusted estimate of efficacy.
b
This (214) is the estimate of missing studies in the pooled analysis of the total dataset rather than the sum of missing studies from the individual drug datasets (205),
and suggests that a further nine studies are missing, probably from those reviews where no adjustment was made because the analysis of publication bias was
underpowered for smaller reviews.
doi:10.1371/journal.pbio.1000344.t002

summarise data from animal studies and more broadly. It seems
highly unlikely that the animal stroke literature is uniquely
susceptible to the factors that drive publication bias. First, there is
likely to be more enthusiasm amongst scientists, journal editors, and
the funders of research for positive than for neutral studies. Second,
the vast majority of animal studies do not report sample size
calculations and are substantially underpowered. Neutral studies
therefore seldom have the statistical power confidently to exclude an
effect that would be considered of biological significance, so they are
less likely to be published than are similarly underpowered
‘‘positive’’ studies. However, in this context, the positive predictive
value of apparently significant results is likely to be substantially
lower than the 95% suggested by conventional statistical testing
[31]. A further consideration relating to the internal validity of
studies is that of study quality. It is now clear that certain aspects of
experimental design (particularly randomisation, allocation concealment, and the blinded assessment of outcome) can have a substantial
impact on the reported outcome of experiments [14]. While the
importance of these issues has been recognised for some years [32],
they are rarely reported in contemporary reports of animal
experiments [33].
The ethical principles that guide animal studies hold that the
number of animals used should be the minimum required to
demonstrate the outcome of interest with sufficient precision. For
some experiments, this number may be larger than those currently
employed. For all experiments involving animals, nonpublication
of data means those animals cannot contribute to accumulating
knowledge and that research syntheses are likely to overstate

Finally, if more than one outcome measure was studied, and if
effect sizes were consistently higher and precision consistently
lower for a particular outcome measure, funnel plot asymmetry
would result. However, because this analysis is restricted to studies
reporting changes in infarct size, such a problem is unlikely to be
an issue here.
In view of the above, it is important to note that, because we
have included all data reporting an effect on infarct volume and
not just the largest effect size from each publication, we will have
included at least some imprecise studies testing ineffective doses (at
the lower end of a dose response curve) or at later time points,
which could lead to a reversal of funnel plot asymmetry. For this
reason, we think that the present study is more likely to
underestimate than to overestimate the effect of publication bias.
For meta-analyses of individual interventions, we do not believe
that these techniques are sufficiently robust to allow the reliable
reporting of a true effect size adjusted for publication bias. This is
partly because most meta-analyses are too small to allow reliable
reporting, but also because the true effect size may be confounded
by many factors, known and unknown, and the empirical
usefulness of a precise estimate of efficacy in animals is limited.
However, these techniques do allow some estimation both of the
presence and of the likely magnitude of publication bias, and
reports of meta-analysis of animal studies should include some
assessment of the likelihood that publication bias confounds their
conclusions, and the possible magnitude of the bias.
These quantitative data raise substantial concerns that publication
bias may have a wider impact in attempts to synthesise and
PLoS Biology | www.plosbiology.org
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Figure 4. Absolute overstatement of efficacy for the ten interventions identified through trim-and-fill as showing significant
publication bias. The vertical error bars represent the 95% confidence intervals of the estimate. The width of each column reflects the log of the
number of contributing experiments.
doi:10.1371/journal.pbio.1000344.g004

biological effects, which may in turn lead to further unnecessary
animal experiments testing poorly founded hypotheses. We
estimate that for the interventions described here, experiments
involving some 3,600 animals have remained unpublished. We
consider this practice to be unethical. Others have considered the
issue of publication bias in animal stroke studies [34], and have
made suggestions for how this might be addressed. Given that a
framework regulating animal experimentation already exists in
most countries, we suggest that this might be exploited to allow the
maintenance of a central register of experiments performed,
grouped according to their broad topic, anonymised if required,
and referenced in publications arising from that work. Those
PLoS Biology | www.plosbiology.org

responsible for preparing conference presentations, review articles,
and books would then be much better placed to make a reasonable
assessment of the extent to which publication bias may confound
their conclusions.

Methods
We conducted a systematic review for reports of the quantitative
impact of publication bias in animal studies by electronic search of
PubMed (4 December 2008) with the search term ‘‘publication
bias’’, limited to ‘‘animals’’. We sought to include publications
reporting a quantitative estimate of publication bias in meta6
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analyses describing the efficacy of interventions in animal models
of human disease. Abstracts were independently screened by two
investigators (ESS, MRM).
We used data from all meta-analyses (published and unpublished) of interventions tested in animal stroke studies reposited in
the database of CAMARADES (an international collaboration
established in 2004 to support meta-analyses of animal data for
stroke), which had been completed by August 2008. These
reviews use a standard methodology including a broad search
strategy, inclusion and exclusion criteria, systematic searching of
multiple online databases, searching of conference abstracts, and
screening of search results by two independent investigators.
They perform well against the 12-item checklist for systematic
reviews of animal studies (Text S2) proposed by Mignini et al.
[35], with a median score of 11 (interquartile range 10.5–11). The
CAMARADES data management system includes an analytical
package to allow weighted and stratified mean difference metaanalysis; included studies are retained in the database for further
analysis, and access to this database is publically available on
request.
The database includes details of each individual experiment,
including effect size and its standard error. The reviews from
which these data are drawn are representative of the literature;
they include 11 of a total of 14 meta-analyses of animal studies of
stroke which had been published by the end of 2008. Of the five
included reviews unpublished at that time (IL1 RA, thrombolytics
other than tPA, growth factors, minocycline, stem cells), one has
been published and two are under review.
Animal stroke studies report a variety of outcome measures,
often measured from the same cohort of animals. To avoid
duplication we have restricted the present analysis to reports of
effects on infarct size. Where this was determined at multiple time
points (for instance using serial MRI), the individual reviews
recorded only the last outcome measured. Where a cohort of
animals was represented more than once in the database (for
instance in studies reporting the effects of tPA and hypothermia in
combination), the overall analysis was censored such that each
cohort appeared only once. No intervention was the subject of
more than one review in the database.
For each experiment, effect size and standard error were
extracted. For each intervention, and for all interventions together
(with individual experiments being pooled for a global analysis),
the prevalence of publication bias was assessed using funnel
plotting [36], Egger regression [37], and the Duval and Tweedie
nonparametric trim-and-fill approach [27] (enabled in METATRIM, an additional module for STATA).
The basis of funnel plotting and Egger regression is that, all
other things being equal, imprecise studies should be as likely to
understate efficacy as to overstate it. Where there is a
preponderance of imprecise studies overstating efficacy, and all
other things being equal, this suggests that imprecise studies
understating efficacy are missing from the analysis, as occurs with
publication bias. This leads to asymmetry in the funnel plot and to
the movement of the Egger regression line y-intercept away from
the origin.
The basis of trim-and-fill is the identification of the publications
contributing most to funnel plot asymmetry, to suppress these from
the analysis, and to recalculate the overall estimate of efficacy.

Studies contributing most to asymmetry around this new overall
estimate are then suppressed, a new estimate calculated, and so the
process continues until no further studies are excluded. Then the
suppressed studies are replaced, along with matching imputed
studies with an effect size calculated by reflection around the
recalculated overall estimate and variance equal to that of the
study which they are balancing. The number of imputed studies
added to the dataset provides an estimate of the number of missing
unpublished studies, and meta-analysis of this enlarged dataset
provides an approximation of what the true efficacy might be were
publication bias not present. We attempted to estimate the extent
of publication bias in the animal stroke literature by measuring the
relative and absolute differences between the observed estimate of
efficacy and the estimated true efficacy.
We tested any relationship between the precision and the
methodological quality of individual studies using a ten-item
study quality checklist comprising peer-reviewed publication,
statement of control of temperature, random allocation to
treatment or control, blinded induction of ischemia, blinded
assessment of outcome, use of anaesthetic without significant
intrinsic neuroprotective activity, appropriate animal model
(aged, diabetic, or hypertensive), sample size calculation,
compliance with animal welfare regulations, and statement of
potential conflict of interests [11]. Despite the potential
shortcomings of using aggregate checklist scores rather than
assessing the impact of individual study quality items [38], across
a range of systematic reviews publications scoring highly on this
checklist tend to give lower estimates of treatment effect; while
the score has not been formally validated it does have face
validity, and has formed the basis for an international consensus
statement of Good Laboratory Practice in the modelling of
ischaemic stroke [39].

Supporting Information
Text S1 References identified in search for previous studies of
publication bias in animal models.
Found at: doi:10.1371/journal.pbio.1000344.s001 (0.04 MB
DOC)
Text S2 Components of the Mignini checklist.
Found at: doi:10.1371/journal.pbio.1000344.s002 (0.02 MB
DOC)
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